Pherecydes Pharma is a French company that specializes in developing antibacterial treatments using bacteriophages to combat antibiotic-resistant infections. With a mission to address the public health challenge of antimicrobial resistance, Pherecydes Pharma has been at the forefront of innovative therapeutic approaches since 2007. Bacteriophages, or phages, are natural viruses that specifically target and destroy bacteria while being harmless to humans.

This targeted approach makes phages a promising treatment option against antibiotic-resistant bacteria. With a decisive focus on phage therapy, Pherecydes Pharma aims to overcome the limitations of antibiotics and the growing threat of bacterial resistance. Their product candidates include anti-Staphylococcus aureus, anti-Escherichia coli, and anti-Pseudomonas-aeruginosa treatments.

The company has already filed four patents, affirming their dedication to research and development in the fight against resistant bacteria. By harnessing the power of phages, Pherecydes Pharma is committed to advancing the field of antibacterial therapies and safeguarding global health